statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Neumora Therapeutics (NASDAQ:NMRA) Shares Gap Up to $12.61

Neumora Therapeutics, Inc. (NASDAQ:NMRA  Get Free Report) gapped up prior to trading on Thursday . The stock had previously closed at $12.61, but opened at $12.98. Neumora Therapeutics shares...

Neumora Therapeutics (NASDAQ:NMRA) Receives "Outperform" Rating from Royal Bank of Canada

Neumora Therapeutics (NASDAQ:NMRA  Get Free Report)s stock had its outperform rating restated by analysts at Royal Bank of Canada in a research report issued to clients...

JPMorgan Chase & Co. Raises Neumora Therapeutics (NASDAQ:NMRA) Price Target to $22.00

Neumora Therapeutics (NASDAQ:NMRA  Free Report) had its target price increased by JPMorgan Chase & Co. from $20.00 to $22.00 in a research report sent to investors on Monday, Benzinga reports...

Neumora Therapeutics (NASDAQ:NMRA) Sees Large Volume Increase Following Analyst Upgrade

Neumora Therapeutics, Inc. (NASDAQ:NMRA  Get Free Report) saw strong trading volume on Monday after JPMorgan Chase  Co. raised their price target on the stock from $20.00 to $22.00...

Neumora Therapeutics to Participate at Stifel 2024 Virtual CNS Days

WATERTOWN, Mass., March 13, 2024 (GLOBE NEWSWIRE) -- Neumora Therapeutics, Inc. (Nasdaq: NMRA), a clinical-stage biopharmaceutical company redefining neuroscience drug development, today announced...

Neumora Therapeutics, Inc.'s (NASDAQ:NMRA) Lock-Up Period Set To Expire Tomorrow

Neumora Therapeutics (NASDAQ:NMRA  Get Free Report) lock-up period will end on Wednesday, March 13th. Neumora Therapeutics had issued 14,710,000 shares in its public offering on...

Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives $21.29 Average Target Price from Analysts

Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA  Get Free Report) have been given a consensus rating of Moderate Buy by the seven analysts that are covering the stock...

Neumora Therapeutics (NASDAQ:NMRA) Issues  Earnings Results, Beats Expectations By $0.05 EPS

Neumora Therapeutics (NASDAQ:NMRA  Get Free Report) announced its quarterly earnings data on Thursday. The company reported ($0.71) EPS for the quarter, topping analysts consensus...

Neumora Therapeutics price target raised by $7 at RBC Capital, here's why

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Neumora Therapeutics reports Q4 EPS (71c), consensus (55c)

Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.

Volume	378,755.00
52-Wk High	$21.00
52-Wk Low	$8.33

NMRA Neumora Therapeutics Inc.

About

Feed

News

Sentiment

Earnings

Fundamentals